Ways to Collaborate
Using AAVantage®-Novel AAV Capsid Evolution and Screening Platform , we have designed and validated several capsid libraries, and developed novel AAV capsid variants for retina and liver-directed human gene therapy.
Products
- Novel AAV capsid for retinal pigmented epithelium (RPE) targeting via intravitreal injection
- Novel immune-evading AAV capsids for liver targeting
- Capsid libraries
Retina-targeting AAV capsid variants
- High tissue specificity for RPE
- Intravitreal delivery
- Selection in NHP
- Transduction efficiency 5x better than AAV2-7m8
Liver-targeting AAV capsid variants with exceptional immune evasion properties
- High specificity for human hepatocytes
- Better transduction efficiency than the current best variant AAV3B-V04
- Exceptional evasion of preexisting neutralizing antibodies
- 3 libraries based on human serotypes
- High transduction efficiency and production yield
- 2 library based on a non-primate AAV
- Evasion of human preexisting neutralizing antibodies
- 1 library based on a non-AAV parvovirus
- Large capacity of genome size (up to 6.1 kb)
Flexible Business Models
Porton Advanced is open to explore R&D partnerships on projects of mutual interest